Table 2.
Baseline characteristics of included studies.
| Study | Intervention (plus calcium and/or vitamin D) | Number of patients | Age (±SD) |
BMI | BMD (lumbar; total hip; femoral neck) in g/cm2 |
BMD (lumbar; total hip; femoral neck) T score |
Duration (months) | Outcomes measured |
Lost to follow-up (intervention versus control) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Alendronate | ||||||||||
|
| ||||||||||
| Orwoll et al. [27] | Placebo or 10 mg/d of alendronate (500 mg/d and 400–450 IU/d) |
Placebo Alendronate |
95 146 |
63 (12) 63 (13) |
25 (3) 25 (3) |
2.2; 2.1; 2.3 2.0; 2.1; 2.2 |
24 | BMD | 17% versus 14% | |
| Vertebral fractures. nonvertebral fractures (secondary endpoints) | ||||||||||
|
| ||||||||||
| Gonnelli et al. [28] | Placebo (calcium) or 10 mg/d of alendronate (1000 mg/d) | Placebo | 38 | 56.6 (10.4) | 24.3 (2.9) | 0.737 (0.103); 0.770 (0.099); 0.632 (0.100) |
36 | BMD. QUS | 6 versus 7 | |
| Alendronate | 39 | 57.2 (9.9) | 24.9 (2.4) | 0.725 (0.110); 0.762 (0.101); 0.622 (0.090) |
||||||
|
| ||||||||||
| Risedronate | ||||||||||
|
| ||||||||||
| Boonen et al. [29] | Placebo or 35 mg of risedronate (1000 mg/d and 450–500 IU/d) | Placebo | 93 | 62 (11) | 25 (4) | 0.824 (0.96); | −3.1 (0.9); | 24 | Lumbar spine BMD BMD at other sites. new vertebral fractures. clinical fractures (secondary endpoints) |
16 versus 18 |
| 0.763 (0.106); NA |
−2.0 (0.7); NA | |||||||||
| Risedronate | 191 | 60 (11) | 25 (4) | 0.809 (0.99); | −3.3 (0.9); | |||||
| 0.768 (0.111); NA |
−2.0 (0.7); NA | |||||||||
|
| ||||||||||
| Ibandronate | ||||||||||
|
| ||||||||||
| Orwoll et al. [30] | Placebo or 150 mg Ibandronate/month | Placebo | 47 | 65.0 (10.6) | 24.8 (3.4) | −2.1 (0.68) | 12 | BMD | 1 | |
| −1.8 (0.70) | ||||||||||
| −2.3 (0.55) | ||||||||||
| Ibandronat | 85 | 63.9 (11.2) | 25.9 (4.1) | −2.1 (0.61) | 3 | |||||
| −1.7 (0.68) | ||||||||||
| −2.2 (0.50) | ||||||||||
|
| ||||||||||
| Miacalcic | ||||||||||
|
| ||||||||||
| Trovas et al. [31] | Placebo or 200 IU/d of miacalcic (1000 mg/d) | Placebo | 13 | 51.6 (10.5) | 25.7 (3.1) | 0.847 | 12 | BMD | 0 | |
| (0.190); NA; | ||||||||||
| 0.753 (0.162) | ||||||||||
| Miacalcic | 15 | 53.3 (13.7) | 26.1 (2.4) | 0.866 | Vertebral fractures | |||||
| (0.124); NA; | ||||||||||
| 0.737 (0.116) | ||||||||||
|
| ||||||||||
| Teriparatide | ||||||||||
|
| ||||||||||
| Trovas et al. [31] | Placebo or 20 or 40 μg Teriparatide/d versus Placebo | Placebo | 147 | 59 (13) | 25 (4) | 0.85 (0.14) | −2.4 (1.2) | 11 | BMD | 24 |
| −1.9 (0.8) | ||||||||||
| −2.7 (0.8) | ||||||||||
| Teriparatide 20 μg/d | 151 | 59 (13) | 25 (4) | 0.89 (0.15) | −2.0 (1.3) | 11 | ||||
| −1.8 (0.8) | ||||||||||
| −2.6 (0.8) | ||||||||||
| Teriparatide 40 μg/d | 139 | 58 (13) | 25 (4) | 0.87 (0.14) | −2.2 (1.2) | 20 | ||||
| −1.9 (0.9) | ||||||||||
| −2.7 (0.8) | ||||||||||
|
| ||||||||||
| Orwoll et al. [32] | Placebo versus Teriparatide 32 μg | Placebo | 10 | 54.5 (2.6) | 25.9 (1.5) | 0.746 (0.03) | −3.3 (0.3) | 18 | BMD | 0 |
| 0.781 (0.02) | −1.7 (0.2) | |||||||||
| 0.650 (0.03) | −2.0 (0.2) | |||||||||
| Teriparatide | 13 | 49.5 (2.9) | 24.3 (1.0) | 0.731 (0.03) | −3.5 (0.2) | 0 | ||||
| 0.774 (0.03) | −1.7 (0.2) | |||||||||
| 0.644 (0.02) | −1.9 (0.2) | |||||||||
Fx, number of patients with one or more fractures.